AMARANTUS THERAPEUTICS, INC. CONVERTIBLE PROMISSORY NOTE AGREEMENT AS AMENDED MARCH 23, 2011Convertible Promissory Note Agreement • June 3rd, 2011 • Amarantus BioSciences, Inc. • Retail-retail stores, nec • California
This Convertible Promissory Note Agreement, dated as of April 22, 2011, (this "Agreement") is entered into by and among Amarantus Therapeutics, Inc., a Delaware corporation (the "Company"), and the persons and entities listed on the schedule of investors attached hereto as Schedule I (each an "Investor" and, collectively, the "Investors").
VERDISYS, INC.Convertible Promissory Note Agreement • August 11th, 2004 • Verdisys Inc • Oil & gas field exploration services
Except as may be indicated by the undersigned below, the undersigned is an “accredited investor,” as that term is defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The undersigned has checked the box below indicating the basis on which he is representing his status as an “accredited investor”:
CONVERTIBLE PROMISSORY NOTE AGREEMENTConvertible Promissory Note Agreement • July 14th, 2011 • Nacel Energy Corp • Electric services
This Convertible Promissory Note Agreement (“Note”) is entered into as of this 23rd day of February 2011, by and betweent JMJ FINANCIAL (“Holder”) and Nacel Energy Corp. (“Writer”), under the terms and conditions set forth herein.
ContractConvertible Promissory Note Agreement • December 3rd, 2008 • Arrowhead Research Corp • Services-commercial physical & biological research • Delaware
THIS NOTE AND ANY SHARES ACQUIRED UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNLESS OTHER EVIDENCE SATISFACTORY TO CALANDO PHARMACEUTICALS, INC. IS PROVIDED CONFIRMING THAT SUCH REGISTRATION IS NOT REQUIRED.
